Jonathan P Sleeman

List of Publications by Year
in descending order

151 papers	14,270 citations	50566 48 h-index	22488 117 g-index
154 all docs	154 docs citations	154 times ranked	22204 citing authors

#	Article	IF	Citations
1	Cancer microenvironment and genomics: evolution in process. Clinical and Experimental Metastasis, 2022, 39, 85-99.	1.7	11
2	Sulfated hyaluronic acid inhibits the hyaluronidase CEMIP and regulates the HA metabolism, proliferation and differentiation of fibroblasts. Matrix Biology, 2022, 109, 173-191.	1.5	10
3	Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis. Cancer Letters, 2022, 533, 215600.	3.2	2
4	Id1 and Id3 Are Regulated Through Matrixâ€Assisted Autocrine BMP Signaling and Represent Therapeutic Targets in Melanoma. Advanced Therapeutics, 2021, 4, 2000065.	1.6	1
5	Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2â^' Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2â^' Breast Cancer. Cancers, 2021, 13, 1810.	1.7	13
6	IER2-induced senescence drives melanoma invasion through osteopontin. Oncogene, 2021, 40, 6494-6512.	2.6	13
7	RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERÎ±)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2. Cells, 2021, 10, 2868.	1.8	2
8	Quantitative Detection of Disseminated Melanoma Cells by Trp-1 Transcript Analysis Reveals Stochastic Distribution of Pulmonary Metastases. Journal of Clinical Medicine, 2021, 10, 5459.	1.0	2
9	A cautionary note: Toxicity of polyethylene glycol 200 injected intraperitoneally into mice. Laboratory Animals, 2020, 54, 391-396.	0.5	7
10	Spatiotemporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics. International Journal of Cancer, 2020, 147, 1190-1198.	2.3	0
11	Guidance of healthcare development for metastatic cancer patients as an example for setting incentives. Clinical and Experimental Metastasis, 2020, 37, 1-5.	1.7	4
12	The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells. Clinical and Experimental Metastasis, 2020, 37, 47-67.	1.7	24
13	Application of ethyl cinnamate based optical tissue clearing and expansion microscopy combined with retrograde perfusion for 3D lung imaging. Experimental Lung Research, 2020, 46, 393-408.	0.5	6
14	RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 (YAP1), Inhibition of the Forkhead Box Protein M1 (FOXM1), and Activation of Forkhead Box Transcription Factor 3A (FOXO3A). Cancers, 2020, 12, 2689.	1.7	5
15	Sociocultural incentives for cancer care implementation. Clinical and Experimental Metastasis, 2020, 37, 561-563.	1.7	5
16	Human innate immune cell crosstalk induces melanoma cell senescence. OncoImmunology, 2020, 9, 1808424.	2.1	5
17	EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. British Journal of Cancer, 2020, 123, 942-954.	2.9	18
18	Assessment of incentivizing effects for cancer care frameworks. Clinical and Experimental Metastasis, 2020, 37, 447-450.	1.7	4

#	Article	IF	Citations
19	Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance. EBioMedicine, 2020, 54, 102699.	2.7	36
20	Loss of ASAP1 in mice impairs adipogenic and osteogenic differentiation of mesenchymal progenitor cells through dysregulation of FAK/Src and AKT signaling. PLoS Genetics, 2019, 15, e1008216.	1.5	27
21	Editorial series: cancer care in low- and middle-income countries. Clinical and Experimental Metastasis, 2019, 36, 477-480.	1.7	9
22	Tspan8 is expressed in breast cancer and regulates Eâ€cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles. Journal of Pathology, 2019, 248, 421-437.	2.1	29
23	Molecules in metastasis. Clinical and Experimental Metastasis, 2019, 36, 69-69.	1.7	0
24	Exciting new article categories introduced not Clinical and Experimental Metastasis: submit your article now!. Clinical and Experimental Metastasis, 2018, 35, 1-2.	1.7	1
25	TGFÎ² counteracts LYVE-1-mediated induction of lymphangiogenesis by small hyaluronan oligosaccharides. Journal of Molecular Medicine, 2018, 96, 199-209.	1.7	23
26	BASIS: High-performance bioinformatics platform for processing of large-scale mass spectrometry imaging data in chemically augmented histology. Scientific Reports, 2018, 8, 4053.	1.6	30
27	Dietary regulation of metastasis. Clinical and Experimental Metastasis, 2018, 35, 713-714.	1.7	4
28	Hyaluronic acid-CD44 interactions promote BMP4/7-dependent Id1/3 expression in melanoma cells. Scientific Reports, 2018, 8, 14913.	1.6	23
29	The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies. Clinical and Experimental Metastasis, 2018, 35, 563-599.	1.7	25
30	Platelet deficiency in Tpoâˆ’/âˆ’ mice can both promote and suppress the metastasis of experimental breast tumors in an organ-specific manner. Clinical and Experimental Metastasis, 2018, 35, 679-689.	1.7	7
31	Effect of Co-presentation of Adhesive Ligands and Short Hyaluronan on Lymphendothelial Cells. Frontiers in Bioengineering and Biotechnology, 2018, 6, 25.	2.0	2
32	Extracellular regulation of BMP signaling: welcome to the matrix. Biochemical Society Transactions, 2017, 45, 173-181.	1.6	40
33	PIPAC puts pressure on peritoneal metastases from pancreatic cancer. Clinical and Experimental Metastasis, 2017, 34, 291-293.	1.7	6
34	Editorial: special issue introduction. Clinical and Experimental Metastasis, 2017, 34, 197-198.	1.7	1
35	CD44 mediates the catch-bond activated rolling of HEPG2Iso epithelial cancer cells on hyaluronan. Cell Adhesion and Migration, 2017, 11, 476-487.	1.1	12
36	Extended publication guidelines for the reporting of clinical research in Clinical and Experimental Metastasis. Clinical and Experimental Metastasis, 2017, 34, 441-442.	1.7	1

#	Article	IF	Citations
37	CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease. PLoS ONE, 2017, 12, e0171748.	1.1	6
38	Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget, 2017, 8, 72281-72301.	0.8	11
39	â€˜Normalizingâ€™ the malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin. Cell Death and Disease, 2016, 7, e2491-e2491.	2.7	15
40	Introduction of revised â€œAims and Scopeâ€•for Clinical & Experimental Metastasis. Clinical and Experimental Metastasis, 2016, 33, 741-742.	1.7	1
41	Collaborative Action of Surface Chemistry and Topography in the Regulation of Mesenchymal and Epithelial Markers and the Shape of Cancer Cells. ACS Applied Materials & Interfaces, 2016, 8, 28554-28565.	4.0	11
42	Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. Cell Reports, 2016, 17, 1344-1356.	2.9	88
43	Footprintless disruption of prosurvival genes in aneuploid cancer cells using CRISPR/Cas9 technology. Biochemistry and Cell Biology, 2016, 94, 289-296.	0.9	7
44	Tin Tungstate Nanoparticles: A Photosensitizer for Photodynamic Tumor Therapy. ACS Nano, 2016, 10, 3149-3157.	7.3	74
45	CD24 Is Not Required for Tumor Initiation and Growth in Murine Breast and Prostate Cancer Models. PLoS ONE, 2016, 11, e0151468.	1.1	11
46	TGF-Î²1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT). PLoS ONE, 2016, 11, e0162221.	1.1	13
47	Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. Oncotarget, 2016, 7, 74846-74859.	0.8	16
48	Tissue inhibitor of metalloproteinases (TIMP)â€1 creates a premetastatic niche in the liver through SDFâ€1/CXCR4â€dependent neutrophil recruitment in mice. Hepatology, 2015, 61, 238-248.	3.6	165
49	A Systematic Approach to Defining the microRNA Landscape in Metastasis. Cancer Research, 2015, 75, 3010-3019.	0.4	56
50	The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. International Journal of Cancer, 2015, 137, 686-697.	2.3	30
51	The lymph node pre-metastatic niche. Journal of Molecular Medicine, 2015, 93, 1173-1184.	1.7	108
52	Pre-metastatic conditioning of organ microenvironments by tumors: beyond preparing the soil. Journal of Molecular Medicine, 2015, 93, 1171-1172.	1.7	6
53	A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene, 2015, 34, 424-435.	2.6	131
54	Hyaluronidase-1 expression promotes lung metastasis in syngeneic mouse tumor models without affecting accumulation of small hyaluronan oligosaccharides in tumor interstitial fluid. Glycobiology, 2015, 25, 258-268.	1.3	16

#	Article	IF	Citations
55	Sugars in the microenvironment: the sticky problem of HA turnover in tumors. Cancer and Metastasis Reviews, 2014, 33, 1059-1079.	2.7	37
56	CD44 is a Multidomain Signaling Platform that Integrates Extracellular Matrix Cues with Growth Factor and Cytokine Signals. Advances in Cancer Research, 2014, 123, 231-254.	1.9	96
57	Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model. Clinical and Experimental Metastasis, 2014, 31, 351-365.	1.7	15
58	Accumulation of small hyaluronan oligosaccharides in tumour interstitial fluid correlates with lymphatic invasion and lymph node metastasis. British Journal of Cancer, 2014, 111, 559-567.	2.9	91
59	The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1Î±â€“Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer. Clinical Cancer Research, 2014, 20, 604-616.	3.2	47
60	Delphinidin is a novel inhibitor of lymphangiogenesis but promotes mammary tumor growth and metastasis formation in syngeneic experimental rats. Carcinogenesis, 2013, 34, 2804-2813.	1.3	16
61	Tumorâ€initiating properties of breast cancer and melanoma cells in vivo are not invariably reflected by spheroid formation in vitro, but can be increased by longâ€term culturing as adherent monolayers. International Journal of Cancer, 2013, 132, E94-105.	2.3	21
62	Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44. Cell Death and Disease, 2013, 4, e819-e819.	2.7	79
63	Hyaluronic acid fragments enhance the inflammatory and catabolic response in human intervertebral disc cells through modulation of toll-like receptor 2 signalling pathways. Arthritis Research and Therapy, 2013, 15, R94.	1.6	81
64	Autochthonous Mouse Melanoma and Mammary Tumors do not Express the Pluripotency Genes Oct4 and Nanog. PLoS ONE, 2013, 8, e57465.	1.1	9
65	CD24 Induces Expression of the Oncomir miR-21 via Src, and CD24 and Src Are Both Post-Transcriptionally Downregulated by the Tumor Suppressor miR-34a. PLoS ONE, 2013, 8, e59563.	1.1	36
66	VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis. Blood, 2012, 120, 1899-1907.	0.6	23
67	The immediate early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal cancer patients. Oncogene, 2012, 31, 3796-3806.	2.6	41
68	RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development. Oncogene, 2012, 31, 4912-4922.	2.6	21
69	The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications. Clinical and Experimental Metastasis, 2012, 29, 737-746.	1.7	32
70	The metastatic niche and stromal progression. Cancer and Metastasis Reviews, 2012, 31, 429-440.	2.7	179
71	Building the niche: The role of the S100 proteins in metastatic growth. Seminars in Cancer Biology, 2012, 22, 216-225.	4.3	125
72	Concepts of metastasis in flux: The stromal progression model. Seminars in Cancer Biology, 2012, 22, 174-186.	4.3	75

#	Article	IF	Citations
73	Metastasis: Understanding is the beginning of order in chaos. Seminars in Cancer Biology, 2012, 22, 173.	4.3	8
74	CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cellular and Molecular Life Sciences, 2012, 69, 435-448.	2.4	50
75	Spatio-Temporal Patterns of Pancreatic Cancer Cells Expressing CD44 Isoforms on Supported Membranes Displaying Hyaluronic Acid Oligomers Arrays. PLoS ONE, 2012, 7, e42991.	1.1	34
76	SnapShot: The Epithelial-Mesenchymal Transition. Cell, 2011, 145, 162-162.e1.	13.5	99
77	LiCl induces TNF-Î± and FasL production, thereby stimulating apoptosis in cancer cells. Cell Communication and Signaling, 2011, 9, 15.	2.7	25
78	Discovery of a novel tumour metastasisâ€promoting gene, NVMâ€1. Journal of Pathology, 2011, 225, 96-105.	2.1	12
79	Lymphangiogenesis and hemangiogenesis: Potential targets for therapy. Journal of Surgical Oncology, 2011, 103, 489-500.	0.8	33
80	Do all roads lead to Rome? Routes to metastasis development. International Journal of Cancer, 2011, 128, 2511-2526.	2.3	119
81	Role of Fibulin-5 in Metastatic Organ Colonization. Molecular Cancer Research, 2011, 9, 553-563.	1.5	24
82	Loss of CD24 expression promotes ductal branching in the murine mammary gland. Cellular and Molecular Life Sciences, 2010, 67, 2311-2322.	2.4	14
83	Multiâ€Gram Synthesis of a Hyaluronic Acid Subunit and Synthesis of Fully Protected Oligomers. Advanced Synthesis and Catalysis, 2010, 352, 2657-2662.	2.1	15
84	ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients. Oncogene, 2010, 29, 2393-2403.	2.6	85
85	Dermal Hyaluronan Is Rapidly Reduced by Topical Treatment with Glucocorticoids. Journal of Investigative Dermatology, 2010, 130, 141-149.	0.3	58
86	Cancer metastasis as a therapeutic target. European Journal of Cancer, 2010, 46, 1177-1180.	1.3	175
87	Cell cycle quiescence can suppress transcription from an ecdysone receptorâ€"based inducible promoter in mammalian cells. BioTechniques, 2009, 46, 433-440.	0.8	9
88	Preclinical Drug Development Must Consider the Impact on Metastasis. Clinical Cancer Research, 2009, 15, 4529-4530.	3.2	34
89	Tumor lymphatics. Seminars in Cancer Biology, 2009, 19, 285-297.	4.3	86
90	Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumorâ€induced lymphangiogenesis in vivo. International Journal of Cancer, 2009, 125, 34-42.	2.3	45

#	Article	IF	Citations
91	Tumor metastasis and the lymphatic vasculature. International Journal of Cancer, 2009, 125, 2747-2756.	2.3	214
92	Delphinidin inhibits a broad spectrum of receptor tyrosine kinases of the ErbB and VEGFR family. Molecular Nutrition and Food Research, 2009, 53, 1075-1083.	1.5	30
93	ADAM10 Is the Constitutive Functional Sheddase of CD44 in Human Melanoma Cells. Journal of Investigative Dermatology, 2009, 129, 1471-1482.	0.3	74
94	Suppression of the Kinase Activity of Receptor Tyrosine Kinases by Anthocyanin-Rich Mixtures Extracted from Bilberries and Grapes. Journal of Agricultural and Food Chemistry, 2009, 57, 3094-3101.	2.4	31
95	Tumor Lymphangiogenesis: What We Know and Don't Know. , 2009, , 93-104.		0
96	Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Experimental Dermatology, 2008, 17, 100-107.	1.4	121
97	Modeling lymphangiogenesis in a three-dimensional culture system. Nature Methods, 2008, 5, 431-437.	9.0	116
98	The Relationship Between Tumors and the Lymphatics: Consequences for Metastasis. , 2008, , 341-350.		0
99	Dermal Fibroblasts Induce Maturation of Dendritic Cells. Journal of Immunology, 2007, 178, 4966-4974.	0.4	58
100	Differential Regulation of Hyaluronan Metabolism in the Epidermal and Dermal Compartments of Human Skin by UVB Irradiation. Journal of Investigative Dermatology, 2007, 127, 687-697.	0.3	138
101	Switch in syndecan-1 and syndecan-4 expression controls maturation associated dendritic cell motility. Experimental Dermatology, 2007, 16, 580-589.	1.4	26
102	Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clinical and Experimental Metastasis, 2007, 24, 587-597.	1.7	220
103	New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. Clinical and Experimental Metastasis, 2007, 24, 707-715.	1.7	55
104	Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clinical and Experimental Metastasis, 2007, 24, 619-636.	1.7	51
105	Tumor-induced lymphangiogenesis: A target for cancer therapy?. Journal of Biotechnology, 2006, 124, 224-241.	1.9	89
106	Complex networks orchestrate epithelialâ€“mesenchymal transitions. Nature Reviews Molecular Cell Biology, 2006, 7, 131-142.	16.1	3,547
107	Aristoforin, a Novel Stable Derivative of Hyperforin, Is a Potent Anticancer Agent. ChemBioChem, 2005, 6, 171-177.	1.3	61
108	Hyperforin acts as an Angiogenesis Inhibitorin vitroandin vivo. Planta Medica, 2005, 71, 999-1004.	0.7	49

#	Article	IF	Citations
109	CD24 Expression Causes the Acquisition of Multiple Cellular Properties Associated with Tumor Growth and Metastasis. Cancer Research, 2005, 65, 10783-10793.	0.4	292
110	Hyaluronan-oligosaccharide-induced transcription of metalloproteases. Journal of Cell Science, 2004, 117, 359-367.	1.2	149
111	Differential immunization identifies PHB1/PHB2 as blood-borne tumor antigens. Oncogene, 2004, 23, 7430-7435.	2.6	45
112	Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA. Journal of Immunological Methods, 2004, 285, 145-155.	0.6	35
113	Early cytoskeletal rearrangement during dendritic cell maturation enhances synapse formation and Ca2+ signaling in CD8+ T cells. European Journal of Immunology, 2004, 34, 2708-2719.	1.6	12
114	Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. International Journal of Cancer, 2004, 111, 184-191.	2.3	42
115	MAZ51, an indolinone that inhibits endothelial cell and tumor cell growthin vitro, suppresses tumor growthin vivo. International Journal of Cancer, 2004, 112, 986-993.	2.3	59
116	Targeting dendritic cells with CD44 monoclonal antibodies selectively inhibits the proliferation of naive CD4+ T-helper cells by induction of FAS-independent T-cell apoptosis. Immunology, 2003, 109, 32-40.	2.0	38
117	Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. Journal of Pathology, 2003, 201, 544-554.	2.1	127
118	Active Detachment Involves Inhibition of Cell-Matrix Contacts of Malignant Melanoma Cells by Secretion of Melanoma Inhibitory Activity. Laboratory Investigation, 2003, 83, 1583-1594.	1.7	66
119	Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-CÎ”NÎ”C- and VEGF-A-induced angiogenesis in vitro. Experimental Cell Research, 2003, 285, 286-298.	1.2	39
120	Hyaluronan â€“ magic glue for the regulation of the immune response?. Trends in Immunology, 2003, 24, 112-114.	2.9	100
121	Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Research, 2003, 63, 713-22.	0.4	143
122	CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes and Development, 2002, 16, 3074-3086.	2.7	445
123	Galectin-3 is strongly up-regulated in nonapoptosing mammary epithelial cells during rat mammary gland involution. Glycobiology, 2002, 12, 129-134.	1.3	17
124	Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4. Journal of Experimental Medicine, 2002, 195, 99-111.	4.2	1,236
125	CD44 variantâ€“specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages. Blood, 2002, 99, 3955-3961.	0.6	33
126	Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene, 2002, 21, 1242-1250.	2.6	236

#	Article	IF	Citations
127	Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. FEBS Journal, 2001, 268, 5530-5540.	0.2	89
128	Markers for the lymphatic endothelium: In search of the holy grail?. Microscopy Research and Technique, 2001, 55, 61-69.	1.2	170
129	Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane. Microscopy Research and Technique, 2001, 55, 100-107.	1.2	19
130	Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO Journal, 2001, 20, 6969-6978.	3.5	1,607
131	Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene, 2001, 20, 3399-3408.	2.6	125
132	Expression of M-N#1, a histo-blood group B-like antigen, is strongly up-regulated in nonapoptosing mammary epithelial cells during rat mammary gland involution. Glycobiology, 2001, 11, 441-449.	1.3	3
133	Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. , 2001, 268, 5530.		4
134	CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. Journal of Cell Science, 2001, 114, 3463-3477.	1.2	40
135	CD44 Acts Both as a Growthâ€•and Invasivenessâ€Promoting Molecule and as a Tumorâ€Suppressing Cofactor. Annals of the New York Academy of Sciences, 2000, 910, 106-120.	1.8	141
136	Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B. Oncogene, 1999, 18, 4485-4494.	2.6	17
137	Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro. Oncogene, 1999, 18, 6692-6699.	2.6	16
138	Characterisation of the murine gene encoding the intracellular hyaluronan receptor IHABP (RHAMM). Gene, 1999, 226, 41-50.	1.0	34
139	CD44 variant exon v5 encodes a tyrosine that is sulphated. FEBS Journal, 1998, 255, 74-80.	0.2	14
140	Problems with RHAMM. Cell, 1998, 95, 591-592.	13.5	34
141	CD44 Variant Isoforms are Essential for the Function of Epidermal Langerhans Cells and Dendritic Cells. Cell Adhesion and Communication, 1998, 6, 157-160.	1.7	27
142	How Tumor Cells Make Use of CD44. Cell Adhesion and Communication, 1998, 6, 141-147.	1.7	39
143	An Essential Role for CD44 Variant Isoforms in Epidermal Langerhans Cell and Blood Dendritic Cell Function. Journal of Cell Biology, 1997, 137, 1137-1147.	2.3	165
144	Variant Exons v6 and v7 Together Expand the Repertoire of Glycosaminoglycans Bound by CD44. Journal of Biological Chemistry, 1997, 272, 31837-31844.	1.6	70

#	Article	IF	Citations
145	Autonomous Neural Axis Formation by Ectopic Expression of the Protooncogene c-ski. Developmental Biology, 1997, 192, 392-404.	0.9	37
146	A Splice Variant of CD44 Expressed in the Rat Apical Ectodermal Ridge Contributes to Limb Outgrowth. Annals of the New York Academy of Sciences, 1996, 785, 345-349.	1.8	14
147	The Role of CD44 Splice Variants in Human Metastatic Cancer. Novartis Foundation Symposium, 1995, 189, 142-156.	1.2	15
148	Tumor metastasis formation: cell-surface proteins confer metastasis-promoting or -suppressing properties. Biochimica Et Biophysica Acta: Reviews on Cancer, 1994, 1198, 1-10.	3.3	25
149	Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Current Opinion in Cell Biology, 1994, 6, 726-733.	2.6	401
150	Cd44 and Splice Variants of Cd44 in Normal Differentiation and Tumor Progression. , 1993, , 265-288.		15
151	Uneven distribution of methylation sites within the human papillomavirus la genome: possible relevance to viral gene expression. Nucleic Acids Research, 1984, 12, 8847-8860.	6.5	32